ライフサイエンスコーパス: antibody to

1 t levels of hemagglutination-inhibition (HI) antibodies to 2010-2011 H3N2v viruses.

2 IgG antibodies to 28 recombinant Pf antigens were measured i

3 Both models found that antibodies to 5 proteins of the Merozoite Surface Protei

4 we measured total levels of immunoglobulin G antibodies to 5 PvDBP variants and used a functional in

5 intraperitoneal administration of a blocking antibody to 6 week-old female NOD/ShiLtJ mice repeatedly

6 screening tests that detect both antigen and antibody to 65 days for the Western blot test.

7 ysium using an immunofluorescence assay, and antibodies to a deamidated gliadine peptide using an imm

8 e negative, eight specimens had neutralizing antibodies to a flavivirus (unable to be identified), an

9 IgG antibodies to a novel antigen were elevated in offspring

10 Covalently binding an alpha-amylase specific antibody to a polyaniline (PANI) layer and controlling d

11 oximity-based labeling approach that uses an antibody to a target antigen to guide biotin deposition

12 The ability of antibodies to accumulate affinity-enhancing mutations in

13 ern immunoblots were performed with specific antibodies to ADAM-10 or ADAM-17.

14 he structure of the HCDR3, similar to bovine antibodies, to aid in recognition of a cluster of conser

15 ting immunity to DENV developed neutralizing antibodies to all 4 serotypes of DENV.

16 Mice produced equivalent titers of antibodies to all viruses as measured by enzyme-linked i

17 n samples from 20 patients with specific IgE antibodies to alpha-gal and 10 controls.

18 The presence of antibodies to angiotensin type 1 receptor (AT1R) and end

19 as directly associated with the titer of IgE antibodies to animal dander.

20 By adding antibodies to antibiotic (ceftriaxone)-treated mice, we

21 en used to quantify the hydrophobicity of an antibody to assess downstream risks.

22 recipients with strong/intermediate binding antibodies to AT1R (P = 0.014) and ETAR (P = 0.005).

23 e observed for recipients with pretransplant antibodies to AT1R (P = 0.19) and ETAR (P = 0.32), but d

24 enters between 2011 and 2013 were tested for antibodies to AT1R and ETAR by the enzyme-linked immunos

25 ponezumab, an anti-amyloid-beta40 selective antibody, to attenuate amyloid-beta accrual in cerebral

26 w the parallel measurement of multiple serum antibodies to autoantigens and peptides.

27 ants have the potential to allow therapeutic antibodies to be produced in virtually any expression sy

28 ntary binding region on all three monoclonal antibodies to be the CDR H3 loop of the Fab region, and

29 ns, often hinders the ability of a candidate antibody to be developed and manufactured.

30 by 2 hours and was detected by an antiapo(a) antibody to be localized to Rab5-positive early endosome

31 IgM is the first antibody to be produced in immune responses and plays an

32 ot only could enable the use of radiolabeled antibodies to become a common practice, but also could s

33 f Bet v 1 inhibited binding of patients' IgE antibodies to Bet v 1.

34 espite a wealth of activating and inhibitory antibodies to beta1 integrins, the conformational states

35 The recent successful use of monoclonal antibodies to block immune regulatory pathways to enhanc

36 To investigate the ability of the antibody to block fusion, we determined the cryoEM struc

37 Here we report studies using a monoclonal antibody to block IFN-alpha/beta receptor (IFNAR) signal

38 Antibodies to Borrelia burgdorferi or autoantigens were

39 llustrate the increased negative impact when antibodies to both HLA and non-HLA antigens are present

40 odies to site VIII competed for binding with antibodies to both of those adjacent neutralizing sites.

41 cline of maternally derived immunoglobulin G antibody to both the EBV viral capsid antigen and EBV nu

42 complex tubulointerstitial nephritis due to antibodies to brush border antigens of the proximal tubu

43 group of a phase 2 trial testing monoclonal antibodies to C. difficile toxins A and B for preventing

44 We measured the ability of vaccine-induced antibodies to capture infectious simian immunodeficiency

45 f the antibody, is biodegradable, and has an antibody to carrier mass ratio of 13, which is greater t

46 We sought to study the relevance of IgE antibodies to cat and dog allergens in an area in which

47 High-titer IgE antibodies to cat and dog allergens were strongly associ

48 brosis markers in HSCs and that neutralizing antibody to CCL5 inhibited activation.

49 Treatment with blocking antibodies to CD1a alleviated skin inflammation.

50 uted to reduced mycobacterial growth because antibodies to CD1b inhibited this effect by 55%.

51 Inolimomab, a monoclonal antibody to CD25, has shown encouraging results in phase

52 Thus, SOD conjugated with antibodies to cell adhesion molecule PECAM (Ab/SOD) inhi

53 Antibodies to cell surface central nervous system protei

54 tial therapeutic usefulness of high-affinity antibodies to cell wall carbohydrates is unquestioned, h

55 d for mapping short reads from ChIP-seq with antibodies to centromeric histone H3 (cenH3).

56 d (iii) reveal that neutralization of CMV by antibodies to certain epitopes in gH or gH/gL is both st

57 s were collected on filter paper to test for antibodies to Chlamydia trachomatis pgp3 using a multipl

58 Fluorescent antibodies to ciliary proteins are used to validate rese

59 eloped antibodies and T cells to PAD and IgG antibodies to citrullinated fibrinogen peptides, in the

60 DBA/2 mice failed to develop antibodies to citrullinated fibrinogen peptides.

61 We recently identified a novel antibody to clade B serpin that reduces islet-associated

62 The ability of many antibodies to cleave antigen, albeit slowly, supports th

63 ple sclerosis (MS), we administered blocking antibody to CLEC12A that significantly ameliorated disea

64 P. yoelii results in increased production of antibodies to cognate antigen.

65 ts novel therapeutic approaches that include antibodies to common gamma cytokines, inhibitors of cyto

66 ne complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and h

67 nd folding and the induction of neutralizing antibodies to conformational B cell epitopes of MSP119 H

68 Modifying antibodies to contain histidine-rich peptides enables re

69 protection and the failure of a neutralizing antibody to correlate with protection against dengue vir

70 17 patients with ocular dSNMG, 4 (23.5%) had antibodies to cortactin.

71 logues are being attached to tumor-targeting antibodies to create antibody-drug conjugates (ADCs), a

72 es, including the ability of vaccine-induced antibodies to cross-neutralize the field strains of HCMV

73 Serological testing for antibodies to Ct antigens is potentially useful for trac

74 An invasion inhibitory monoclonal antibody to CyRPA blocks binding of CyRPA to PfRh5 and c

75 unofluorescence using commercially available antibodies to cytokeratin, vimentin, and CD45.

76 e the most potent and broad HIV-neutralizing antibodies to date.

77 of the most potent and broadly neutralizing antibodies to date.

78 ells can be isolated from the ovary using an antibody to DDX4, there is no good in silico modelling t

79 ted the capacity of anti-receptor monoclonal antibodies to deliver vaccine components to skin DC subs

80 ly blocked the binding of a non-neutralizing antibody to Delta123, while having reduced ability to bl

81 emic areas where the population has acquired antibodies to dengue.

82 the therapeutic activity of human monoclonal antibodies to DENV EDE for their ability to control ZIKV

83 e present study used rituximab, an anti-CD20 antibody, to deplete B cells in M. tuberculosis-infected

84 ggregation and masked the ability of several antibodies to detect Abeta.

85 flow and mass cytometry, Abseq uses specific antibodies to detect epitopes of interest; however, unli

86 Using a novel antibody to detect active NOTCH3, we report here that NO

87 Here, we engineered a bispecific antibody to detect K11/K48-linked chains and identified

88 longitudinal cohort of 300 Kenyan children, antibodies to different AMA1 and MSP2 alleles of merozoi

89 be completely recapitulated using monoclonal antibodies to different epitopes.

90 ity of agonists, and the inherent failure of antibodies to differentiate between the large number of

91 ttenuated by metalloproteinase inhibitors or antibodies to disintegrin metalloproteinase 8 (ADAM8), a

92 Antibodies to DNA and chromatin drive autoimmunity in sy

93 l cell population in its entirety when using antibodies to DNER and NFIA.

94 ccepted F-LR + MPR platelets; none developed antibodies to donor lymphocytes.

95 blocking peptide, as well as a neutralizing antibody to E-cadherin, works synergistically with ioniz

96 ndwich ELISA and the specific recognition of antibody to E. coli O157:H7, the sensitive detection of

97 However, the reactivity of IgE antibody to each allergen was not affected by food proce

98 s but instead suggested anamnestic recall of antibody to earlier influenza virus strains.

99 We then assessed the seroprevalence of antibodies to Ebola virus in a cross-sectional study of

100 Because neutralizing antibodies to EDE have therapeutic potential against ZIK

101 onstructed by immobilization of NGAL capture antibodies to electropolymerized aniline deposited on to

102 The ability of these antibodies to elicit Fc-dependent effector functions has

103 on synergizes with tumor-specific monoclonal antibodies to eliminate human tumor xenografts by enhanc

104 when the mice were treated with a monoclonal antibody to eliminate residual granulocyte activity.

105 require the use of (surrogate) mouse or rat antibodies to enable optimal interactions with murine ef

106 process in which B lymphocytes evolve potent antibodies to encountered antigens and generate immune m

107 Furthermore, we assessed the ability of the antibody to enter the tumor by in silico and in vivo met

108 sed surface which is capable of loading more antibodies to entrap the antigen.

109 In a second step, a second antibody to ERBB2 quantitatively detects the bound analy

110 hIVIG, which contained neutralizing antibodies to EV-D68, reduced paralysis in infected mice

111 No neutralizing antibodies to evolocumab were detected.

112 aporin was conjugated to a Siglec-8-specific antibody to examine the targeting of an agent to these c

113 No neutralizing antibodies to factor VIII were detected.

114 viability of human neutrophils via agonistic antibodies to Fas and Siglec-9.

115 In multivariable analysis IgE antibodies to Fel d 1 and Can f 5 were each associated w

116 Levels of antibody to pertussis toxin, antibody to filamentous hemagglutinin, and antibody to p

117 Subjects with antibodies to FN/Col-IV had more acute rejection than di

118 In the case-control study, antibodies to FN/Col-IV were more prevalent during year

119 Phospho-specific antibodies to four of these sites established that serin

120 resulting in alterations to the full-length antibody-to-fragment ratio.

121 humans and with glycan-binding proteins and antibodies to gather information about the structures of

122 tiumlike structures was impaired not only by antibodies to gB or gH/gL but also by antibodies to the

123 nd conjugated them with anti-ZIKV monoclonal antibodies to generate anti-ZIKV-PSBs.

124 Antibodies to H5 and H7 were measured by means of hemagg

125 detectable hemagglutination-inhibiting (HAI) antibody to H7N9 were enrolled.

126 was associated with low-level heterosubtypic antibodies to H9 and H7, but not to H5 AI virus.

127 is can have a major impact on the ability of antibodies to halt viral replication.

128 Antibodies to HBsAg were detected only in mice injected

129 antibody to HBsAg status, serial changes in antibody to HBsAg levels, and donor serology, were not a

130 ivity, and changes in liver biochemistry and antibody to HBsAg levels.

131 ther clinical parameters, including baseline antibody to HBsAg status, serial changes in antibody to

132 binding and activity of broadly neutralizing antibodies to HCV.

133 .6 million noninstitutionalized persons with antibody to HCV (anti-HCV).

134 total number and prevalence of persons with antibody to HCV in 2010.

135 administration of glucagon receptor-blocking antibody to healthy individuals increased plasma glucago

136 erval [CI] 9.4%-19%) in 388 patients who had antibodies to hepatitis B core antigen only versus 5.0%

137 ionalized persons age 6 years and older for: antibody to hepatitis B core antigen (anti-HBc), indicat

138 epatitis B surface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc)-positive

139 0.21 (95% CI 0.14-0.32) versus patients with antibody to hepatitis B core antigen only.

140 should screen (hepatitis B surface antigen, antibody to hepatitis B core antigen, and antibody to he

141 use of conflicting studies about whether the antibody to hepatitis B surface antigen (anti-HBs) prote

142 dicative of chronic (current) infection; and antibody to hepatitis B surface antigen (anti-HBs), indi

143 Antibody to hepatitis B surface antigen was tested 1 mon

144 n, antibody to hepatitis B core antigen, and antibody to hepatitis B surface antigen) for HBV in high

145 ore, this study investigated how preexisting antibodies to historical influenza viruses influenced HA

146 e has reliably elicited broadly neutralizing antibodies to HIV in humans or animal models.

147 RV144 induced antibodies to HIV that were partially protective against

148 animals have shown that broadly neutralizing antibodies to HIV-1 can prevent infection, suggesting th

149 3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on t

150 AMR is caused by donor-specific antibodies to HLA, which contribute to TAV by initiating

151 ox models revealed that men with circulating antibodies to HPV-6, -11, -16, or -18 were not less like

152 lly protective against infection, as well as antibodies to HSV.

153 ese IVIG fragments, nor agonistic monoclonal antibodies to human Fas or Siglec-9 affected the viabili

154 Natalizumab (NTZ), a monoclonal antibody to human alpha4beta1/beta7 integrin, is an effe

155 antagonism mechanism by which the binding of antibodies to HVR1 blocks the binding and activity of br

156 ity, we used a panel of broadly neutralizing antibodies to identify the immunogenic sites of a domina

157 These proteins complement immune cells and antibodies to identify, tag, destroy, and eliminate path

158 antibodies to merozoites did not decline and antibodies to IE surface antigens expressing virulent ph

159 universal; some key functional responses and antibodies to IEs were better maintained and these may c

160 atients with metastatic disease had elevated antibodies to IGFBP2, p53, HER2-ICD, HER2-ECD, and CEA,

161 glycol thiols, neutravidin and biotinylated antibodies to immobilize bacteria.

162 ta expressing murine IL-12 (G47Delta-mIL12), antibodies to immune checkpoints (CTLA-4, PD-1, PD-L1),

163 vantage of the selectivity of the monoclonal antibody to increase the efficacy of the chemotherapeuti

164 e malaria tend to be more seroprevalent than antibodies to infected erythrocytes from children with n

165 ated that in areas where malaria is endemic, antibodies to infected erythrocytes from children with s

166 nvasion (ISI) assay to assess the ability of antibodies to inhibit sporozoite infection of hepatocyte

167 KI, we utilized a specific function-blocking antibody to inhibit alphavbeta5 in a rat model of renal

168 dition of nivolumab (anti-programmed death-1 antibody) to ipilimumab (anti-cytotoxic T-cell lymphocyt

169 We developed monoclonal antibodies to its intracellular and extracellular domain

170 mutated immune state or after reverting each antibody to its unmutated preimmune ancestor.

171 s reactivation (BK viremia or JC viruria) on antibodies to kidney-specific self-antigens is unknown.

172 FRET does not require genetic engineering or antibodies to label receptors.

173 ation of FRET donor and acceptor anti-PrP(C) antibodies to living cells yielded a measure of PrP(C) s

174 , administering agonist anti-CD40 monoclonal antibody to LNG-treated mice at 1 dpi restored lung T ce

175 The development of antibodies to low molecular weight haptens remains chall

176 Antibodies to LPS and flagellin have been described as i

177 n the spinal cord using a saporin-conjugated antibody to Mac1, we demonstrate a causal role for micro

178 The ability of an antibody to make an effective immunotoxin could not be p

179 As previously reported, antibodies to Matrin 3 primarily stain nuclei, but the i

180 e phenomenon for the ability of neutralizing antibodies to mediate protective effects in vivo is unde

181 ence of 97.61% compared with the fluorescent-antibody-to-membrane-antigen (FAMA) test.

182 In contrast, complement-fixing antibodies to merozoites did not decline and antibodies

183 Administration of FGF2 neutralizing antibody to mice bearing experimental liver metastases p

184 tic production of IgM and class-switched IgG antibodies to microbial capsular polysaccharides, which

185 Furthermore, naturally occurring catalytic antibodies to microbial determinants have been correlate

186 Delivery of antibodies to monitor key biomarkers of retinopathy in v

187 te the utility of employing an anti-idiotype antibody to monitor a patient's specific immune response

188 ATP ectonucleotidases and/or anti-PD-1/PD-L1 antibodies to more effectively treat this disease.

189 at vaccination elicited functional antiviral antibodies to multiple neutralizing sites in rhesus maca

190 important insights on the efficacy of human antibodies to Mycobacterium tuberculosis and on how func

191 iments using antibody transfer indicate that antibodies to NA have an important role in protection.

192 n serum albumin, blocks binding of all three antibodies to nab-paclitaxel when added in excess.

193 of serotype-cross-reactive and type-specific antibodies to neutralization.

194 Antibodies to nonstructural protein 1 (NS1) were largely

195 We identify human monoclonal antibodies to O-antigens that are highly protective in m

196 ltered DC function had greater production of antibody to P. gingivalis, greater IL-12 expression, and

197 gests that administration of CTLA-4 blocking antibodies to patients who express high levels of CTLA-4

198 ion; (2) immunoprecipitation of plasma using antibodies to PCSK9 and immunodetection of apo(a); (3) E

199 Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein convertase subtilisin/kexi

200 Therapeutic use of blocking antibodies to PD-L1 or its receptor PD-1 has produced un

201 Removing antibody to perform an HLA-incompatible (HLAi) living do

202 , antibody to filamentous hemagglutinin, and antibody to pertactin were measured in maternal blood be

203 Maternal antibodies to pertussis can hamper infant immune respons

204 Levels of antibody to pertussis toxin, antibody to filamentous hem

205 Pathogenic antibodies to PF4/heparin bind and activate cellular Fcg

206 tal reports (P < 0.001) and reports with IgE antibodies to PHO (P = 0.008) and SUX (P = 0.001) at tim

207 sponses to TNP-Ficoll, production of natural antibodies to phosphocholine, and survival after intrana

208 Using a monoclonal antibody to plant cell wall xyloglucan, we show that thi

209 ining malaria transmission on maintenance of antibodies to Plasmodium falciparum merozoite antigens a

210 secreting cells that cause the deposition of antibodies to polymorphic recipient antigens (ie, alloan

211 nes from 2004 to 2009 for cross-neutralizing antibodies to potential pandemic strains.

212 lop RSV vaccines and vaccine-like monoclonal antibodies to prevent acute RSV LRTI.

213 t for glycosylation remodeling of monoclonal antibodies to produce homogeneous intact antibody glycof

214 sensitive to immune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1).

215 We conclude that the ability of CD4i antibodies to promote VRC01 association with Env trimers

216 he FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type

217 Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type

218 ted effector cell population cooperates with antibody to protect against genital chlamydia and establ

219 uence (RosettaAntibody) and then docking the antibody to protein antigens (SnugDock).

220 lass correlation coefficients (ICCs) between antibodies to quantify interassay variability for PD-L1

221 a horseradish-peroxidase-tagged (HRP) mouse antibody to quantify binding.

222 s study, the ability of different monoclonal antibodies to recognize, inhibit, or activate mouse BAFF

223 ric mean concentrations (GMCs) of cord blood antibodies to recombinant pertussis toxin (PT) and filam

224 al residues that can be targeted by blocking antibody to reduce infection, and determines that it bin

225 We found that while antibodies to region II are highly abundant, circulating

226 odies competitively inhibited binding of IgE antibodies to Rhi o 1 up to 70% and suppressed allergen-

227 s the most predominant antibody subclass and antibodies to rLinB-13 did not cross react with Lu. long

228 d that administration of cis P-tau targeting antibody to rodents reduces or delays pathological featu

229 body complexes after binding of RSV-specific antibodies to RSV antigens expressed on the surface of i

230 stvaccination concentrations of neutralizing antibodies to RV5 were negatively correlated with prevac

231 d when her serum sample was found to contain antibodies to S-arrestin, a retinal protein and potent c

232 tudy duration, and lacked serum neutralising antibodies to serotype-3 poliovirus.

233 Antibodies to site VIII competed for binding with antibo

234 Antibodies to SP1, CA6 and PSP occur in some patients wi

235 herapy and combine the ability of monoclonal antibodies to specifically target tumour cells with the

236 type 2 inflammatory patterns, including IgE antibodies to staphylococcal superantigens; several stud

237 As a strong inducer of IgE antibodies to substituted ammonium ion epitopes (QAI), p

238 owing abortion in a majority of the animals, antibodies to surface proteins persisted beyond the dura

239 able, from no severe effects attributable to antibodies, to sustained reticulocytopenia, to near-fata

240 Along with neutralizing toxins, antibodies to TcdA26-39 (but not to toxoids), whether ra

241 No neutralizing antibodies to the ADC or antibody were detected, despite

242 of the Hex nanocarrier to deliver functional antibodies to the cytosol by employing anti-beta-tubulin

243 nanocarrier capable of delivering functional antibodies to the cytosol.

244 nancy to optimize transplacental transfer of antibodies to the fetus.

245 ty to influenza viral antigens, particularly antibodies to the HA and NA glycoproteins.

246 st likely has to induce broadly neutralizing antibodies to the HIV-1 envelope glycoprotein (Env) spik

247 We also demonstrate multiplexed detection of antibodies to the HPV16 proteins E2, E6, and E7, which a

248 ercome this challenge, we generated specific antibodies to the mouse oxytocin receptor and examined r

249 and their nationwide registers to search for antibodies to the N-methyl-D-aspartate receptor (NMDAR)

250 th myasthenia gravis (MG) without detectable antibodies to the nicotinic acetylcholine receptor (AChR

251 ed the endosomal membranes and delivered the antibodies to the nucleoli of the cells.

252 nly by antibodies to gB or gH/gL but also by antibodies to the pentamer, suggesting a potential role

253 Inoculation of p13Bri in mice elicited antibodies to the peptide and the beta-sheet secondary s

254 Levels of natural antibodies to the pneumococcal polysaccharide component

255 ic factors that influenced the prevalence of antibodies to the rabies vaccine.

256 Cross-reactive neutralizing antibodies to the RSV and HMPV fusion (F) proteins have

257 tralizing activity of serum immunoglobulin G antibodies to the RSV prefusion (pre-F), postfusion (pos

258 ) we applied site-specific immobilization of antibodies to the solid surface that avoids loss of biol

259 may aid the design of immunogens that elicit antibodies to the trimer apex.

260 d decreased binding by narrowly neutralizing antibodies to the V3 crown.

261 Infection with influenza virus induces antibodies to the viral surface glycoproteins hemaggluti

262 could influence the binding of neutralizing antibodies to the virus.

263 ions result from the specific binding of the antibody to the beta-subunit of Fsh to block its action.

264 f a T-cell-depleting anti-CD8beta monoclonal antibody to the controller animals led to a specific dec

265 ent of C57BL/6 or NOD mice with a monoclonal antibody to the CSF-1 receptor resulted in depletion of

266 Binding of a modulatory antibody to the cysteine-rich domain liberates the catal

267 step delivery of premixed sample and labeled antibody to the detection region.

268 The reactivity of IgE antibody to the extracted protein did not differ among t

269 ive (18)F-FDG PET to monitor therapy with an antibody to the insulinlike growth factor 1 receptor (IG

270 NPs were conjugated with anti-EpCAM antibody to the NP surface for immunospecific targeting.

271 Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interl

272 Antibody to the scavenger receptor CD36 reduced the inte

273 Additionally, we generated a novel antibody to the unique human frameshift peptide epitope,

274 ntibody-binding behavior, but delivered more antibodies to their cytosolic targets at a faster rate.

275 d by blocking access of broadly neutralizing antibodies to their epitopes.

276 ely bind fungal cells and recruit endogenous antibodies to their surfaces, resulting in immune-mediat

277 Antibodies to these targets, including CD56/neural cell

278 Serologic testing shows that antibodies to this region correlate with serum neutraliz

279 Further studies evaluating antibodies to this subset of Pf antigens as biomarkers o

280 yroid autoimmunity refers to the presence of antibodies to thyroperoxidase or thyroglobulin, or thyro

281 d by these cells, and addition of anti-NKp46 antibodies to TIL cultures abrogated the ability of thes

282 ian time period of 10 years and analyzed for antibodies to tissue transglutaminase (anti-TG2A) using

283 easure serum endomysial antibodies (EMA) and antibodies to tissue transglutaminase (tTG) were develop

284 administration, or systemic injections of an antibody to TNF before or during sensitization and chall

285 atrices often use molecular anchors, such as antibodies, to trap nanoparticulates.

286 There is increased interest in using antibodies to treat and cure HIV infection.

287 dely used scaffold for developing monoclonal antibodies to treat human diseases.

288 ical rationale for the use of ADCC-optimized antibodies to treat tumors harboring this EGFR isoform.

289 We developed recombinant antibodies to trimethylated lysine residues on histone H

290 ganglion neurons were immunoreactive for an antibody to TRPV4, as assessed by calcium imaging.

291 veloped by IDEXX laboratories, which detects antibodies to two M. bovis proteins, MPB70 and MPB83.

292 chain reaction (PCR)- and the prevalence of antibodies to two P. falciparum antigens (MSP-1, AMA-1).

293 Whether RAS activation, mucosal ILCs and antibodies to V2 are also important hallmarks of HIV-vac

294 endpoint was the change from baseline in IgG antibody to varicella-zoster virus-specific glycoprotein

295 , delivery of an isoform-specific monoclonal antibody to VEGF165b versus control antibody enhanced pe

296 rodiagnosis accomplished by the detection of antibodies to virulence-associated antigens such as CPAF

297 etected on viruses following incubation with antibodies to VZV gE ( approximately 100%), Rab11 (50%),

298 2 and Skerritt monoclonal and two polyclonal antibodies to well-defined gluten protein types (GPT) is

299 Antibodies to Zika virus (ZIKV) can be protective.

300 three ELISAs for the detection of IgM class antibodies to ZIKV, including the Centers for Disease Co